Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

De Hert, Marc, Detraux, Johan, van Winkel, Ruud, Yu, Weiping, Correll, Christoph U.·2012·Nature Reviews Endocrinology
DOI 10.1038/nrendo.2011.156

Cited by (1,000)

Items 701–800 of 1,000

  1. Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics
    Karolina Skonieczna‐Żydecka, Igor Łoniewski, Ewa Stachowska, Wojciech M. Marlicz, Christoph Ulrich Correll · 2020 · The International Journal of Neuropsychopharmacology
  2. Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study
    Kate Merritt, Ana Catalán, Samuel Cowley, Arsime Demjaha, Matthew John Taylor, Philip K. McGuire, Ruth E Cooper, Paul Morrison · 2020 · Journal of Psychopharmacology
  3. Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients
    Jakub Tomasik, Nitin Rustogi, Julie Rask Larsen, Michelle Iris Jakobsen, Camilla Kara Svensson, Louise Vedtofte, Mathilde S. L. Jakobsen, Hans Søe Riis Jespersen, Kamuran Koyuncu, Ole Schjerning et al. · 2020 · Schizophrenia Bulletin Open
  4. Trends and characteristics of extra-medical use of quetiapine among people who regularly inject drugs in Australia, 2011–2018
    Rachel Sutherland, Rashmi Jayathilake, Amy Peacock, Paul Dietze, Raimondo Bruno, Siobhan Reddel, Natasa Gisev · 2021 · Drug and Alcohol Dependence
  5. VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia
    Barbara Jones Warren, Dawn M. Vanderhoef, Jessica Johnson · 2021 · Issues in Mental Health Nursing
  6. Long-term safety and effectiveness of open-label lurasidone in antipsychotic-Naïve versus previously treated adolescents with Schizophrenia: A post-hoc analysis
    Christoph Ulrich Correll, Michael Tocco, Andrei Pikalov, Jay Hsu, ROBERT S. GOLDMAN · 2022 · Schizophrenia Research
  7. Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase®
    Florentia Kaguelidou, Zaba Valtuille, Geneviève Durrieu, Richard Delorme, Hugo Peyre, Jean‐Marc Tréluyer, François Montastruc, Laurent Chouchana · 2022 · Drug Safety
  8. Plasma soluble P-selectin correlates with triglycerides and nitrite in overweight/obese patients with schizophrenia
    Katelynn A. Bourassa, Teodor T. Postolache, Aline Dagdag, Dietmar Fuchs, Olaoluwa O. Okusaga · 2020 · Pteridines
  9. Bilateral Basal Ganglion Hemorrhage after Severe Olanzapine Intoxication
    Kerstin Schweyer, Bastian Fatke, Kornelia Kreiser, Christian Rabe, Christian Ludwig Seifert, Benno David Ikenberg · 2020 · Case Reports in Psychiatry
  10. Improving of Cognition and Quality of Life in Schizophrenia With One-month and Three-month Paliperidone Palmitate Treatment
    Chen-Lin Chang, Yong-Chen Huang, Pin-Chen Yang, For-Wey Lung · 2021 · Research Square
  11. Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting
    Christoph Ulrich Correll, Andrew J. Cutler, François Laliberté, Guillaume Germain, Sean D. MacKnight, Julien Boudreau, Sally W. Wade, Nadia Azmi Nabulsi, Huy‐Binh Nguyen, Mousam Parikh · 2025 · Annals of General Psychiatry
  12. Dietary challenges and desired support strategies in patients with severe mental illness: insights from a qualitative focus group study
    E. Neumann, Simone Rössler, Steffan Vetter, Erich Seifritz, Florian Hotzy, S. Mötteli · 2025 · Nutritional neuroscience
  13. Probiotics, psychobiotics, and postbiotics: a therapeutic modality for the management of schizophrenia
    Sumel Ashique, Debasmita Paul, Biplab Debnath, Dinesh Kumar Chellappan, Joy Das, Utpal Bhui, Mohhammad Ramzan, Neha Sharma, Bimlesh Kumar, Sathvik Belagodu Sridhar et al. · 2025 · Nutritional Neuroscience
  14. Establishing a Care Continuum for Cardiometabolic Conditions for Patients with Serious Mental Illness
    Karly A. Murphy, G. Daumit · 2023 · Current Cardiology Reports
  15. Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS)
    Εleni Stamoula, Vasileios‐Periklis Stamatellos, Theofanis Vavilis, Ioannis Dardalas, Georgios Papazisis · 2023 · Expert Opinion on Drug Safety
  16. DNA methylation may partly explain psychotropic drug-induced metabolic side effects: results from a prospective 1-month observational study
    Céline Dubath, Eleonora Porcu, Aurélie Delacrétaz, Claire Grosu, Nermine Laaboub, Marianna Piras, Armin von Gunten, Philippe Conus, Kerstin Jessica Plessen, Zoltán Kutalik et al. · 2024 · Clinical Epigenetics
  17. Medication non-adherence and self-inflicted violence behaviors among 185,800 patients with schizophrenia in the community: a 12-year cohort study
    Chuanlong Zuo, Xianmei Yang, Xiangrui Wu, Ruoxin Fan, Jun Liu, Xiang Hu, Yang Li, Xing Zhao, Xiang Liu, Yuanyuan Liu · 2024 · BMC Medicine
  18. Antipsychotic-Induced Weight Gain: What Have We Learned?
    Akshatha Silas, Margaret Musso, Trygve Dolber · 2025 · Current Cardiovascular Risk Reports
  19. Akkermansia muciniphila ameliorates olanzapine-induced metabolic dysfunction-associated steatotic liver disease via PGRMC1/SIRT1/FOXO1 signaling pathway
    Hui Chen, Ting Cao, Chenquan Lin, Shimeng Jiao, Yifan He, Zhenyu Zhu, QiuJin Guo, R. Wu, Hualin Cai, Bikui Zhang · 2025 · Frontiers in Pharmacology
  20. Characterization of the white matter networks in schizophrenia patients with metabolic syndrome undergoing risperidone or clozapine treatment
    Xinyan Wu, Xinyue Chen, Kaike Liao, Rui Yu, Yu‐Wei Chen, Kang Li, Nian Liu · 2025 · Frontiers in Neuroscience
  21. Valproate is associated with early decrease of high‐density lipoprotein cholesterol levels in the psychiatric population
    Aurélie Delacrétaz, Anaïs Glatard, Céline Dubath, Mehdi Gholam, Franziska Gamma, Armin von Gunten, Philippe Conus, Chin B. Eap · 2021 · Basic & Clinical Pharmacology & Toxicology
  22. A ganglionic blocker and adrenoceptor ligands modify clozapine-induced insulin resistance
    Jessica W. Y. Yuen, Claire Wu, Cathy K. Wang, David D. Kim, Ric M. Procyshyn, William J. Panenka, William G. Honer, Alasdair M. Barr · 2021 · Psychoneuroendocrinology
  23. Cost-effectiveness analysis of physical activity interventions for people with schizophrenia or bipolar disorder: systematic review
    Hua-Jie Jin, O. Kolawole, Zheng-Wei Wang · 2023 · British Journal of Psychiatry
  24. Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
    Weronika Barbara Grywińska, Aleksandra Głowacka · 2023 · Postępy Psychiatrii i Neurologii
  25. Antipsychotics and Mortality in Adult and Geriatric Patients with Schizophrenia
    Ling‐Ling Yeh, Wei‐Chen Lee, Kuei‐Hong Kuo, Yi‐Ju Pan · 2023 · Pharmaceuticals
  26. Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments
    Núria Saigí-Morgui, Frederik Vandenberghe, Aurélie Delacrétaz, Lina Quteineh, Eva Choong, Mehdi Gholam‐Rezaee, Pierre Julius Magistretti, Jean‐Michel Aubry, Armin von Gunten, Martin Preisig et al. · 2015 · Journal of Clinical Psychopharmacology
  27. Aminotransferase levels as a prospective predictor for the development of metabolic syndrome in patients with schizophrenia
    Eun Young Kim, Se Hyun Kim, Nam Young Lee, Jin Sang Yoon, Chul Eung Kim, Yong Sik Kim, Yong Min Ahn · 2014 · Psychopharmacology
  28. A highly sensitive fluorescence quenching method for perphenazine detection based on its catalysis of K 2 S 2 O 8 oxidizing rhodamine 6G
    Lihong Zhang, Qitong Huang, Chang‐Qing Lin, Xiaofeng Lin, Yiqun Huang, Jiaming Liu, Xudong Ma · 2014 · Journal of Luminescence
  29. Quels critères pour un traitement antipsychotique idéal ?
    Régis Bordet · 2015 · L Encéphale
  30. Reducing health inequalities for people with serious mental illness
    Nutmeg Hallett, Helen Rees · 2017 · Nursing Standard
  31. A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers
    Demet Sağlam Aykut, Evrim Özkorumak Karagüzel · 2017 · Psychiatry and Clinical Psychopharmacology
  32. Real-world data on new users of atypical antipsychotics: characterisation, prescription patterns, healthcare costs and early cardio-metabolic occurrences from a large Italian database
    Carlo Pasquale Piccinni, Letizia Dondi, Giulia Ronconi, Silvia Calabria, Immacolata Esposito, Antonella Pedrini, Aldo Pietro Maggioni, Corrado Barbui, Nello Martini · 2020 · European Journal of Clinical Pharmacology
  33. The architecture of co-morbidity networks of physical and mental health conditions in military veterans
    Aaron F. Alexander‐Bloch, Armin Raznahan, Russell Taki Shinohara, Samuel R. Mathias, Harini Bathulapalli, Ish P. Bhalla, Joseph Lucien Goulet, Theodore Daniel Satterthwaite, Danielle S. Bassett, David C. Glahn et al. · 2020 · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences
  34. Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients
    Fayçal Mouaffak, Florian Ferreri, Julie Bourgin, Emmanuelle Baloche, Olivier J. Blin, Pierre Vandel, Ricardo Pablo Garay, Pierre Vidailhet, Emmanuelle Corruble, Pierre‐Michel Llorca · 2021 · Expert Opinion on Pharmacotherapy
  35. Schizophrenia Patients With Prevotella-Enterotype Have a Higher Risk of Obesity
    Ying Liang, Yang Shen, Gaofei Li, Ye Yuan, Meng Zhang, Jiayu Gao · 2022 · Frontiers in Psychiatry
  36. Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study
    Luísa Monteiro Burin, Margaret Hahn, Neusa Sica da Rocha, Thérèse van Amelsvoort, Agna A. Bartels‐Velthuis, Richard Bruggeman, Lieuwe de Haan, Frederike N. Schirmbeck, Claudia J.P. Simons, Jim van Os et al. · 2022 · Psychiatry Research
  37. Cardiometabolic Risk and Monitoring in Psychiatric Disorders
    Katherine Samaras · 2016 · Springer eBooks
  38. Correlation between brain damage, associated biomarkers, and medication in psychiatric inpatients: A cross-sectional study
    Madoka Yoshida, Tetsuto Kanzaki, Mutsumi Mizoi, Mizuho Nakamura, Takeshi Uemura, Seisuke Mimori, Yoriyasu Uju, Keisuke Sekine, Yukihiro Ishii, Taro Yoshimi et al. · 2016 · Clinica Chimica Acta
  39. Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study
    Vasiliki Mamakou, Sophie Hackinger, Eleni Zengini, Evgenia I. Tsompanaki, Eirini Marouli, Ioannis Serafetinidis, Bram Peter Prins, Athina Karabela, Eirini Glezou, Lorraine Southam et al. · 2018 · BMC Psychiatry
  40. Metabolic Adverse Effects of Low‐Dose Quetiapine: A Systematic Review and Meta‐Analysis
    Pedro Sonim, Rui M. Ferreira, Inês Lourenço, Lia Paula Nogueira Sousa Fernandes, Ana Rita Ferreira · 2025 · Acta Psychiatrica Scandinavica
  41. Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study
    Natalia Jimeno Bulnes, Verónica Velasco, Inmaculada Fierro, Mercedes Duran, Alfonso Carvajal · 2021 · Scientific Reports
  42. Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders
    Hoda Moteshafi, Simon Zhornitsky, Sarah Brunelle, Émmanuel Stip · 2012 · Drug Safety
  43. Sex differences in autonomic adverse effects related to antipsychotic treatment and associated hormone profiles
    Ingrid Torp Johansen, Nils Eiel Steen, Linn Nilsen Rødevand, Synve Hoffart Lunding, Gabriela Hjell, Monica B E G Ormerod, Ingrid Agartz, Ingrid S. Melle, Trine Vik Lagerberg, Mari Nerhus et al. · 2024 · Schizophrenia
  44. Characteristics of Comorbid Physical Disease in Patients With Severe Mental Illness in South Korea: A Nationwide Population-Based Study (2014-2019)
    Eun Jin Na, Jung Sun Lee, Jee Hoon Sohn, Mi Yang, Yoomi Park, Hyun-Bo Sim, Haewoo Lee · 2024 · Psychiatry Investigation
  45. Improving the physical health of overweight/obese people suffering from severe mental disorders: What is the role of antipsychotic drugs and of lifestyle psychosocial interventions?
    Gaia Sampogna, Matteo Di Vincenzo, Mario Luciano, Bianca Della Rocca, Enrico D’Ambrosio, Antonio Rampino, Mario Amore, Pietro Calcagno, Alessandro Rossi, Rodolfo Rossi et al. · 2024 · Journal of Psychiatric Research
  46. Spatial metabolomics in mental disorders and traditional Chinese medicine: a review
    Chaofang Lei, Jiaxu Chen, Zhigang Chen, Chongyang Ma, Xudong Chen, Xiongxing Sun, Xukun Tang, Jun Deng, Shiliang Wang, Jun‐Lin Jiang et al. · 2025 · Frontiers in Pharmacology
  47. The impacts of antipsychotic medications on eating-related outcomes: A mixed methods systematic review
    Rasha Alkholy, Karina Lovell, Penny Bee, Rebecca Pedley, Helen Louise Brooks, Richard Drake, Prathiba Chitsabesan, Anam Bhutta, Abigail Brown, Rebecca Jenkins et al. · 2025 · PLoS ONE
  48. Does life expectancy vary by disability status in LMICs?: A systematic review and meta-analysis
    Desta Debalkie Atnafu, Femke Bannink Mbazzi, Mezgebu Yitayal, Hannah Kuper · 2025 · African Journal of Disability
  49. The development of the Metabolic-associated Fatty Liver Disease during pharmacotherapy of mental disorders - a review
    Jakub Krzysztof Rogalski, Aleksandra Subdys, Oliwia Gawlik-Kotelnicka · 2022 · Current Problems of Psychiatry
  50. Psychotic-like experiences are associated with physical disorders in general population: A cross-sectional study from the NESARC II
    David Sleurs, Caroline Dubertret, Baptiste Pignon, Sarah Tebeka, Yann Le Strat · 2022 · Journal of Psychosomatic Research
  51. Lipid Metabolism Disturbances During Antipsychotic Treatment for Schizophrenia
    Shin Ono, Toshiyuki Someya · 2022 · Springer eBooks
  52. Glucose and Lipid Profiles Predict Anthropometric Changes in Drug-Naïve Adolescents Starting Treatment with Risperidone or Sertraline: A Pilot Study
    Emilia Matera, Gloria Cristofano, Flora Furente, Lucia Marzulli, Martina Tarantini, Lucia Margari, Francesco Maria Piarulli, Andrea DE GIACOMO, Maria Giuseppina Petruzzelli · 2022 · Biomedicines
  53. The relationship of cardiovascular disease risk, clozapine antipsychotic use and cognitive function in a large Chinese schizophrenia cohort
    Chenghao Lu, Xiaoying Jin, Nannan Liu, Yanzhe Li, Yeqing Dong, Xinxu Wang, Shen Li, Jie Li · 2024 · Brain Research
  54. Metabolic syndrome and antipsychotic therapy of schizophrenia
    Н. Н. Петрова, Natalia V. Semenova · 2024 · S S Korsakov Journal of Neurology and Psychiatry
  55. Increased mortality risk in people with schizophrenia in Lithuania 2001–2020
    Mingailė Drevinskaitė, Augustė Kačėnienė, Arūnas Germanavičius, Giedrė Smailytė · 2025 · Schizophrenia
  56. Behavioural interventions for reducing weight gain in schizophrenia
    Guy Faulkner, Markus J. Duncan, Margaret Hahn, Gary J. Remington, Tony A. Cohn · 2013 · Cochrane Database of Systematic Reviews
  57. A review and study of aspirin utilization for the primary prevention of cardiovascular events in a psychiatric population
    Kaitlyn Victor, Megan K. Skelly, Kimberly B. Mulcahy, Tammie Lee Demler, Eileen Trigoboff · 2018 · International Clinical Psychopharmacology
  58. Renewed call for lifestyle interventions to address obesity among individuals with serious mental illness in the COVID-19 era and beyond
    Kelly A. Aschbrenner, John A. Naslund, Jeffrey D Reed, Jeffrey C. Fetter · 2021 · Translational Behavioral Medicine
  59. Applying Care Coordination Principles to Reduce Cardiovascular Disease Risk Factors in People With Serious Mental Illness: A Case Study Approach
    Karly A. Murphy, Arlene Dalcin, Emma Elizabeth McGinty, Stacy Goldsholl, Ann Heller, Gail L. Daumit · 2021 · Frontiers in Psychiatry
  60. Association between Empathy and Clinical Symptoms among Overweight and Non-Overweight Chinese Chronic Schizophrenia Patients
    Yuchen Li, Rui‐Chen‐Xi Luo, Dongmei Wang, Xiangyang Zhang · 2023 · Brain Sciences
  61. Association of clinical variables and thyroid-stimulating hormone with psychotic symptoms in patients with first-episode and drug-naïve major depressive disorder with elevated fasting blood glucose: preliminary exploratory study with a large sample
    Qian Yang, Qianjin Wang, Pu Peng, Tieqiao Liu, Xiangyang Zhang · 2024 · BJPsych Open
  62. Factores determinantes del riesgo metabólico en el tratamiento con antipsicóticos atípicos
    Clara Margarita Franch Pato, Vicente Molina Rodríguez, Juan Ignacio Franch Valverde · 2016 · Psiquiatría Biológica
  63. Assessing Statewide All-Cause Future One-Year Mortality: Prospective Study With Implications for Quality of Life, Resource Utilization, and Medical Futility
    Yanting Guo, Zheng Gang, Tianyun Fu, Shiying Hao, Chengyin Ye, Le Zheng, Modi Liu, Minjie Xia, Bo Jin, Chunqing Zhu et al. · 2018 · Journal of Medical Internet Research
  64. Effects of Long-Term Multimodal Psychosocial Treatment on Antipsychotic-Induced Metabolic Changes in Patients With First Episode Psychosis
    Martina Rojnić Kuzman, Dina Bošnjak Kuharić, Ivana Kekin, Porin Makarić, Zoran Madžarac, Ana Koricancic Makar, Suzan Kudlek Mikulić, Žarko Bajić, Petra Bistrović, Dora Bonacin et al. · 2018 · Frontiers in Psychiatry
  65. Lipid Disturbances in Adolescents Treated With Second-Generation Antipsychotics
    Aurélie Delacrétaz, Frederik Vandenberghe, Anaïs Glatard, Céline Dubath, Axel Levier, Mehdi Gholam‐Rezaee, Laurent Holzer, Anne‐Emmanuelle Ambresin, Philippe Conus, Chin B. Eap · 2019 · The Journal of Clinical Psychiatry
  66. Extra‐medical use of antipsychotics: what can be learnt from experiences with other prescription medicines?
    Natasa Gisev, Jonathan Brett, Amy Peacock · 2019 · Addiction
  67. Prise en charge des comorbidités cardio-vasculaires chez les jeunes patients souffrant d’une psychose débutante : état des lieux et perspectives thérapeutiques
    Ariel Frajerman, V. Morin, Boris Chaumette, Oussama Kébir, Marie‐Odile Krebs · 2020 · L Encéphale
  68. Functional clustering methods for longitudinal data with application to electronic health records
    Bret Zeldow, James Flory, Alisa J. Stephens‐Shields, Marsha A. Raebel, Jason Roy · 2020 · Statistical Methods in Medical Research
  69. Role of artificial intelligence and internet of things based medical diagnostics smart health care system for a post-COVID-19 world
    Sanjay Kumar Sinha · 2023 · Elsevier eBooks
  70. Amélioration de la santé cardiovasculaire par l’exercice physique chez les individus atteints de schizophrénie : un guide de pratique
    Claire Chalfoun, Amal Abdel‐Baki, Elaine D. Letendre, C. Proulx, Antony D. Karelis · 2014 · Obésité
  71. Health Care Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment
    Yawen Jiang, Weiyi Ni · 2015 · Journal of Managed Care & Specialty Pharmacy
  72. Sex-specific association between the albumin D–element binding protein gene and metabolic syndrome in patients with bipolar disorder and schizophrenia
    Eun Young Kim, Se Hyun Kim, Hyun Jeong Lee, Bora Kim, Yong Sik Kim, Yong Min Ahn · 2016 · Psychiatry Research
  73. Gut Microbiota and Antipsychotics Induced Metabolic Alteration
    Dong-Yu Kan, Sujuan Li, Chenchen Liu, Renrong Wu · 2019 · Global Clinical and Translational Research
  74. Clozapine's Multiple Cellular Mechanisms: What Do We Know after More than Fifty Years? a Systematic Review and Critical Assessment of Translational Mechanisms Relevant for Innovative Strategies in Treatment-Resistant Schizophrenia
    Andrea de Bartolomeis, Licia Vellucci, Annarita Barone, Mirko Manchia, Vincenzo De Luca, Felice Iasevoli, Christoph Ulrich Correll · 2022 · SSRN Electronic Journal
  75. Genome Wide Association Study ( GWAS ) Identifies Novel Genetic Loci for Second‐Generation Antipsychotics ( SGA )‐Induced Metabolic Syndrome ( MetS )
    Nihal M. El Rouby, Aniwaa Owusu Obeng, Michael H Preuss, Simon Lee, Mingjian Shi, Rajiv Nadukuru, Sara L. Van Driest, Jonathan D. Mosley, Melissa P. DelBello · 2025 · Clinical and Translational Science
  76. The impact of a ball sports combination training program on physical fitness and body mass Index in children with autism spectrum disorder
    Haiyong Mao, Kai Qi, Shuqiao Meng, Kelong Cai, Lina Zhu, Wei-Ke Zhang, Zhiyuan Qiao, Yang Yang, Aiguo Chen · 2025 · Frontiers in Pediatrics
  77. Clinical and molecular implications of antipsychotics in MASLD
    Celina Gonzalez-Peña, Misael Uribe, Norberto Carlos Chávez-Tapia · 2025 · Annals of Hepatology
  78. Antipsychotic Misuse: A Silent but Growing Public Health Hazard
    Sumeet Bhardwaj, Karisma Pathak, Myra McLenon, Steven Spector, Karen Tu · 2025 · Cureus
  79. Unravelling the role of the gut microbiome in antipsychotic-induced weight gain and metabolic dysfunction in humans and rodents: A systematic review
    Maximilian Tufvesson‐Alm, Louise Walsh, Sinead Pierce, Finola Keohane, Gerard A. Clarke, Karen M. O’Connor, J.F. Cryan, Harriët Schellekens · 2026 · Dialogues in Clinical Neuroscience
  80. The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials
    Mike Trott, Urška Arnautovska, D. J. G. Johnston, Gabrielle Ritchie, Dan J. Siskind · 2026 · BJPsych Open
  81. Weight Gain is Not Associated with Antipsychotic Medication, Sociodemographic Factors, or Diagnosis in a Welsh Secure Mental Health Unit
    Joseph Lloyd Davies, Andrew A. Watt, Ruth Bagshaw, Charlotte Hill, Catherine Heidi Seage · 2023 · International Journal of Forensic Mental Health
  82. Group-Based Trajectory Modeling to Identify Patterns of Antipsychotic-Associated Weight Gain Among Children and Adolescents
    Ning Lyu, Susan Abughosh, Tyler Jordan Varisco, Ying Lin, Paul J. Rowan, Hua Chen · 2024 · Journal of Clinical Psychopharmacology
  83. Exploring Risk Factors for Adverse Reactions in Children with an Acute Psychotic Episode Using the Global Trigger Tool: Does Age Matter?
    Dmitriy V. Ivashchenko, Nina I. Buromskaya, Шиманов Павел Викторович, Yuriy S. Shevchenko, Dmitriy A. Sychev · 2024 · Journal of Child and Adolescent Psychopharmacology
  84. The Impact of Adjunctive Aripiprazole on Olanzapine‐Induced Metabolic Adverse Effects in Patients With Schizophrenia: A Systematic Review
    Stephen Simmons, Soban Sadiq · 2025 · Neuropsychopharmacology Reports
  85. An update on lipid profile screening in second-generation antipsychotic users in the USA
    Elaine H. Morrato · 2012 · Clinical Lipidology
  86. The value of counting WHO-defined cardiovascular risk factors for death and disability in a national sample of adults with psychosis
    Lisa Anne Hahn, Andrew James Mackinnon, Debra L. Foley, Vera Anne Morgan, Anna J Waterreus, Gerald Francis Watts, David Jonathan Castle, Dennis Liu, Cherrie Ann Galletly · 2016 · Schizophrenia Research
  87. In silico strategy for isoform-selective 5-HT 2A R and 5-HT 2C R inhibitors
    Xiaohui Geng, Ying Wang, Huibin Wang, Baichun Hu, Junhao Huang, Yiheng Wu, Jian Wang, Fengjiao Zhang · 2021 · Molecular Systems Design & Engineering
  88. Off-label antipsychotic use patterns among Texas Medicaid adults 2013–2016
    Shuang Chen, Jamie C. Barner, Eun Cho · 2021 · Journal of Comparative Effectiveness Research
  89. Diabetes mellitus prevalence in Northland New Zealand schizophrenia patients on clozapine
    Ashley Cherian Abraham, N. M. McGrath, Verity Humberstone · 2022 · New Zealand Medical Journal
  90. Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials
    Mingjun Zhao, Bin Qin, Yage Mao, Hailing Wang, Aiqin Wang, Chuansheng Wang · 2022 · Neuropsychiatric Disease and Treatment
  91. Cardiotoxicity of current antipsychotics: Newer antipsychotics or adjunct therapy?
    Zheng Liu, Mo-Lin Zhang, Xin-Ru Tang, Xiaoqing Li, Jing Wang, Liliang Li · 2022 · World Journal of Psychiatry
  92. Sex-specific associations between metabolic hormones, severe mental disorders and antipsychotic treatment.
    I. Johansen, N. E. Steen, L. Rødevand, M. Werner, S. H. Lunding, G. Hjell, M. Ormerod, I. Agartz, I. Melle, T. Lagerberg et al. · 2022 · Psychoneuroendocrinology
  93. Is the CYP2D6 Genotype Associated with Antipsychotic-Induced Weight Gain?
    Gesche Jűrgens, Benjamin Skov Kaas‐Hansen, Merete Nordentoft, Thomas Mears Werge, Stig Ejdrup Andersen · 2022 · Journal of Personalized Medicine
  94. Characteristics and Correlates of Metabolic Syndrome in Adolescents with Unipolar and Bipolar Depression: Results from a Cross-National Inpatient Case–Control Study
    Rikinkumar S. Patel, Pradipta Majumder, Christoph Ulrich Correll · 2022 · Journal of Child and Adolescent Psychopharmacology
  95. Addressing Health Inequities in People with Serious Mental Illness
    Leopoldo J. Cabassa · 2023
  96. Special Population: Adults with Severe and Persistent Mental Health Disorders
    Kathleen Barnhouse, Sandra Clark, Jessica Waters Davis · 2023 · Springer eBooks
  97. Abnormal blood lipid and electrocardiogram characteristics in common mental disorders
    Yan Li, Chaohua Tang, Weibo Wu, Zhijian Li, Xuesong Li, Wei Huang, Wensheng Chen, Xiancong Mai, Xiaoling Li, Caixia Xu et al. · 2023 · BMC Psychiatry
  98. Impaired thyroid hormone sensitivity exacerbates the effect of PM2.5 and its components on dyslipidemia in schizophrenia
    Jintao Liu, Yinguang Fan, Jian Guo Song, Rong Song, Xuanxuan Li, Li Liu, Ning Wei, Jiajun Yuan, Weizhuo Yi, Rubing Pan et al. · 2024 · The Science of The Total Environment
  99. Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021
    Charlotte Greene, Luke A. K. Blackbourn, Stuart J. McGurnaghan, Stewart William Mercer, Daniel J. Smıth, Sarah H. Wild, Honghan Wu, Caroline Jackson · 2024 · British Journal of Clinical Pharmacology
  100. Strategies to Address the Metabolic Burden of Psychotropic Medications
    Angelina Anthamatten, Queen Henry-Okafor · 2025 · The Journal for Nurse Practitioners